GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Awakn Life Sciences Corp (OTCPK:AWKNF) » Definitions » Net Income Including Noncontrolling Interests
中文

Awakn Life Sciences (Awakn Life Sciences) Net Income Including Noncontrolling Interests : $-5.16 Mil (TTM As of Oct. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Awakn Life Sciences Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Awakn Life Sciences's Net Income Including Noncontrolling Interests for the three months ended in Oct. 2023 was $-0.47 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Oct. 2023 was $-5.16 Mil.

Awakn Life Sciences Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Awakn Life Sciences's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Awakn Life Sciences Net Income Including Noncontrolling Interests Chart

Awakn Life Sciences Annual Data
Trend Jan21 Jan22 Jan23
Net Income Including Noncontrolling Interests
-0.87 -13.05 -7.19

Awakn Life Sciences Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.19 -2.12 -1.25 -1.33 -0.47

Awakn Life Sciences Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Oct. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Awakn Life Sciences Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Awakn Life Sciences's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Awakn Life Sciences (Awakn Life Sciences) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Awakn Life Sciences Corp (OTCPK:AWKNF) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
TSXV:KNE XCNQ:BETR TSXV:XRTX XCNQ:CHGX XCNQ:DRUG TSXV:HEM XCNQ:BLAB XCNQ:TRYP TSXV:RKV TSX:AEZS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
954:Germany AWKN:Canada
Address
301?217 Queen Street West, Toronto, ON, CAN, M5V 0R2
Website
https://www.awaknlifesciences.com
Awakn Life Sciences Corp is a clinical-stage biotechnology company intended to develop therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder. The Company focuses on Alcohol Use Disorder (AUD), a condition affecting the people in the US and key international markets and many people globally for which the current standard of care is inadequate, enabling to provide breakthrough therapeutics to addiction sufferers in desperate need.

Awakn Life Sciences (Awakn Life Sciences) Headlines

From GuruFocus

CEO Presenting on the Emerging Growth Conference on June 22 Register Now

By PurpleRose PurpleRose • 07-11-2022

CEO Presenting on the Emerging Growth Conference on June 22 Register Now

By GuruFocusNews GuruFocusNews • 06-21-2022

KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th

By PRNewswire PRNewswire • 10-11-2021

CEO Presenting on the Emerging Growth Conference on June 22 Register Now

By GuruFocusNews GuruFocusNews • 07-01-2022